| Artificial intelligence–enabled rapid diagnosis of patients with COVID-19 X Mei, HC Lee, K Diao, M Huang, B Lin, C Liu, Z Xie, Y Ma, PM Robson, ... Nature medicine 26 (8), 1224-1228, 2020 | 1115 | 2020 |
| Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer VP Balachandran, M £uksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Nature 551 (7681), 512-516, 2017 | 1067 | 2017 |
| A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M £uksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520, 2017 | 639 | 2017 |
| Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer LA Rojas, Z Sethna, KC Soares, C Olcese, N Pang, E Patterson, J Lihm, ... Nature 618 (7963), 144-150, 2023 | 540 | 2023 |
| A predictive fitness model for influenza M £uksza, M Lässig Nature 507 (7490), 57-61, 2014 | 457 | 2014 |
| Introductions and early spread of SARS-CoV-2 in the New York City area AS Gonzalez-Reiche, MM Hernandez, MJ Sullivan, B Ciferri, ... Science 369 (6501), 297-301, 2020 | 427 | 2020 |
| COVID-19 in patients with lung cancer J Luo, H Rizvi, IR Preeshagul, JV Egger, D Hoyos, C Bandlamudi, ... Annals of Oncology 31 (10), 1386-1396, 2020 | 313 | 2020 |
| Neoantigen quality predicts immunoediting in survivors of pancreatic cancer M £uksza, ZM Sethna, LA Rojas, J Lihm, B Bravi, Y Elhanati, K Soares, ... Nature 606 (7913), 389-395, 2022 | 139 | 2022 |
| Predictive modeling of influenza shows the promise of applied evolutionary biology DH Morris, KM Gostic, S Pompei, T Bedford, M £uksza, RA Neher, ... Trends in microbiology 26 (2), 102-118, 2018 | 127 | 2018 |
| Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer A Ravi, MD Hellmann, MB Arniella, M Holton, SS Freeman, V Naranbhai, ... Nature genetics 55 (5), 807-819, 2023 | 74 | 2023 |
| Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers K Vanshylla, C Fan, M Wunsch, N Poopalasingam, M Meijers, C Kreer, ... Cell host & microbe 30 (1), 69-82. e10, 2022 | 51 | 2022 |
| Fundamental immune–oncogenicity trade-offs define driver mutation fitness D Hoyos, R Zappasodi, I Schulze, Z Sethna, KC de Andrade, DF Bajorin, ... Nature 606 (7912), 172-179, 2022 | 47 | 2022 |
| Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma F Maura, EH Rustad, V Yellapantula, M £uksza, D Hoyos, KH Maclachlan, ... Leukemia 34 (5), 1476-1480, 2020 | 45 | 2020 |
| Garvan Institute of Medical Research; Prince of Wales Hospital; Royal North Shore Hospital; University of Glasgow; St Vincent’s Hospital; QIMR Berghofer Medical Research … VP Balachandran, M £uksza, JN Zhao, V Makarov, JA Moral, R Remark, ... Institute for Molecular Bioscience, 512-516, 2017 | 44 | 2017 |
| Hybrid gene origination creates human-virus chimeric proteins during infection JSY Ho, M Angel, Y Ma, E Sloan, G Wang, C Martinez-Romero, ... Cell 181 (7), 1502-1517. e23, 2020 | 41 | 2020 |
| Fierce selection and interference in B-cell repertoire response to chronic HIV-1 A Nourmohammad, J Otwinowski, M £uksza, T Mora, AM Walczak Molecular biology and evolution 36 (10), 2184-2194, 2019 | 41 | 2019 |
| Population immunity predicts evolutionary trajectories of SARS-CoV-2 M Meijers, D Ruchnewitz, J Eberhardt, M £uksza, M Lässig Cell 186 (23), 5151-5164. e13, 2023 | 26 | 2023 |
| Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer D Memon, AJ Schoenfeld, D Ye, G Fromm, H Rizvi, X Zhang, MR Keddar, ... Cancer Cell 42 (2), 209-224. e9, 2024 | 19 | 2024 |
| Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave MM Hernandez, AS Gonzalez-Reiche, H Alshammary, S Fabre, Z Khan, ... Nature Communications 12 (1), 3463, 2021 | 18 | 2021 |
| Artificial intelligence for rapid identification of the coronavirus disease 2019 (COVID-19) X Mei, HC Lee, M Huang, B Lin, C Liu, Z Xie, Y Ma, PM Robson, M Chung, ... MedRxiv, 2020.04. 12.20062661, 2020 | 10 | 2020 |
Taha MerghoubAssociate Professor, MSKVerified email at mskcc.org
